Sarepta Therapeutics said early Tuesday that a patient had died after receiving its gene therapy Elevidys, which treats the ...

Opens in a new tab or window A young person with Duchenne muscular dystrophy died following treatment with the recently approved gene therapy ... The patient died after experiencing acute liver ...

Sarepta Therapeutics said Tuesday that a 16-year-old boy died after receiving Elevidys, its gene therapy for Duchenne ... have also contributed to the patient’s death, putting him at heightened ...

It was also revealed that the patient had a recent cytomegalovirus infection, which may have contributed to the liver damage. In general, Elevidys therapy should be postponed in patients with ...

WASHINGTON (AP) — Sarepta Therapeutics said Tuesday that a patient died while taking its closely watched gene therapy for muscular ... from an Alabama woman after a record 130 days The House ...

WEDNESDAY, March 19, 2025 (HealthDay News) -- A patient has died while receiving Elevidys, a gene therapy for Duchenne muscular dystrophy, marking the first known death linked to the treatment.

Sarepta Therapeutics said it will update its prescribing information for Elevidys® (delandistrogene moxeparvovec-rokl) after acknowledging the sudden death of a patient with Duchenne muscular ...

A patient has died while receiving Elevidys, a gene therapy for Duchenne muscular dystrophy, marking the first known death linked to the treatment. The company behind the drug, Sarepta ...

Sarepta Therapeutics said Tuesday that a young man died after receiving Elevidys, its gene therapy for Duchenne muscular dystrophy. It is the first known death linked to the treatment.